PROTOKOLwiki
COMPOUNDS / PSYCHEDELIC / AYAHUASCA
PSYCHEDELIC

AYAHUASCA

MEDIUM RISK
BEST FOR:Mood●●●●●●●○○○7/10
AYAHUASCA · YAGÉ · YAJE · CAAPI · HOASCA · DAIME · VEGETAL · NATEMA · NIXI PAE · LA PURGA
PsychedelicEntheogenicAmazonianMAOIDMTPlant Brew

Amazonian plant brew combining DMT with MAO-inhibiting beta-carbolines, producing prolonged psychedelic effects.

ROUTE / DOSAGE
LOW30mL
STANDARD50-100mL
HIGH150mL+
Note: DMT content varies widely by brew preparation; typical brew contains ~0.5-1mg DMT per mL
CYCLE
Infrequent ceremonial use no established dosing cycle
BIOAVAILABILITY
Variable oral DMT normally inactive orally but MAOIs in brew enable oral absorption
ACTIVE DURATION
4-6h (subjective)
STORAGE
Refrigerate brewed liquid keep dried plant materials cool dry and away from direct light
HALF-LIFE
1-2h (DMT component) (plasma)
DURATION BREAKDOWN
Total4-6h
Onset20-60min
Come up30-60min
Peak1-2h
Offset1-2h
After effects2-6h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Vivid visual hallucinations and altered perception
Profound introspective and emotional experiences
Purging (vomiting) as a common somatic effect
Altered sense of time and self
Mood elevation and antidepressant after-effects
Changes in electrophysiological brain oscillations
Enhanced mindfulness and self-acceptance measures
§ 02 — RISKS
Five fatalities reported in the literature following ayahuasca use
Psychiatric events including agitation, aggression, and exacerbation of psychotic symptoms
Seizures and rhabdomyolysis reported in case reports
Abortifacient and teratogenic effects demonstrated in animal models at higher doses
Potential toxicity with co-administration of certain medications due to MAO inhibition
Nausea, vomiting, and cardiovascular effects (tachycardia, hypertension)
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

A randomized placebo-controlled trial demonstrated rapid antidepressant effects of a single ayahuasca dose in treatment-resistant depression, with significant improvements persisting at 7 days (Cohen's d = 1.49). Retrospective and preclinical studies suggest potential for alcohol use disorder and substance use disorders, with ayahuasca blocking abuse-related effects of alcohol in animal models. Evidence for depression and SUD is the most consistent, while preliminary data exist for PTSD, grief, eating disorders, and neurodegenerative conditions. However, controlled studies remain few, with small sample sizes, single-dose designs, and short follow-ups. A systematic review of adverse events found ayahuasca generally safe in controlled settings, but documented psychiatric and physiological harms including five fatalities in the literature.

§ 06 — SOURCES
[1]
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
pubmed.ncbi.nlm.nih.gov ↗
[2]
Ayahuasca: Uses, Phytochemical and Biological Activities
pubmed.ncbi.nlm.nih.gov ↗
[3]
Ayahuasca for the treatment of alcohol use disorder
pubmed.ncbi.nlm.nih.gov ↗
[4]
Ayahuasca's therapeutic potential: What we know - and what not
pubmed.ncbi.nlm.nih.gov ↗
[5]
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov ↗
[6]
Ayahuasca: pharmacology, safety, and therapeutic effects
pubmed.ncbi.nlm.nih.gov ↗
[7]
Ayahuasca and the traveller: A scoping review of risks and possible benefits
pubmed.ncbi.nlm.nih.gov ↗
[8]
Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review
pubmed.ncbi.nlm.nih.gov ↗
[9]
PsychonautWiki - Ayahuasca
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT